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A Sub-Type of Familial Pancreatic
Cancer: Evidence and Implications of
Loss-of-Function Polymorphisms in
Indoleamine-2,3-Dioxygenase-2
Avinoam Nevler, MD, Alexander J Muller, PhD, Joseph A Cozzitorto, BA, Austin Goetz, MD,
Jordan M Winter, MD, FACS, Theresa P Yeo, PhD, MPH, MSN, Harish Lavu, MD, FACS,
Charles J Yeo, MD, FACS, George C Prendergast, PhD, Jonathan R Brody, PhD
BACKGROUND: Variation in an individual’s genetic status can impact the development of pancreatic ductal
adenocarcinoma; however, the majority of familial pancreatic cancers (FPC) cannot yet be
attributed to a specific inherited mutation. We present data suggesting a correlation between
loss-of-function single nucleotide polymorphisms (SNPs) in an immune regulator gene,
indoleamine-2,3-dioxygenase-2 (IDO2), and an increased risk of FPC.
STUDY DESIGN: Germline DNA from patients who underwent resection for pancreatic ductal adenocarci-
noma (n ¼ 79) was sequenced for the IDO2 SNPs R248W and Y359Stop. Genotypes result-
ing in inactivation of IDO2 (Y325X homozygous, R248W homozygous) were labeled as
homozygous, and the other genotypes were grouped as wild-type or heterozygous. Geno-
type distributions of each SNP were analyzed for Hardy-Weinberg deviation. A genotype
frequency set from the 1000 Genomes Project (n ¼ 99) was used as a genetic control for
genotype distribution comparisons.
RESULTS: A significant 2-fold increase in the overall prevalence of the Y359Stop homozygous genotype
compared with the expected Hardy-Weinberg equilibrium was noted (p < 0.05). Familial
pancreatic cancer was noted in 15 cases (19%) and comparison of the FPC cohort set to the
genetic control set showed a 3-fold increase in Y359Stop homozygous rates (p ¼ 0.054).
Overall in our cohort, the homozygous genotype group was associated with increased risk of
FPC (odds ratio 5.4; 95% CI 1.6 to 17.6; p < 0.01). Sex, age at diagnosis, and history of
tobacco use were not found to be significantly associated with FPC.
CONCLUSIONS: Our preliminary data suggest a strong association between the IDO2 inactivating Y359Stop
SNP and an increased risk of FPC when compared with the control group. Future studies
will evaluate the value of IDO2 genotyping as a prognostic, early detection marker for
pancreatic ductal adenocarcinoma and a predictive marker for novel immune checkpoint
therapies. (J Am Coll Surg 2018;226:596e603.  2018 The Authors. Published by Elsev-
ier Inc. on behalf of the American College of Surgeons. This is an open access article under
the CC BY-NC-ND license [http://creativecommons.org/licenses/by-nc-nd/4.0/])
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Pancreatic ductal adenocarcinoma (PDA) will soon
become the second leading cause of cancer-related deaths
in the US.1 Although the majority of PDAs are sporadic,
roughly 10% are classified as familial pancreatic cancer
(FPC).2 Although different definitions of FPC are found
in the literature, a common practice is to define the famil-
ial form of PDA as instances in which multiple family
members (first-degree relatives) are afflicted with PDA.3,4
Thorough genomic and epidemiologic analyses of fa-
milial registries have identified FPC cases and have pro-
vided the field with important insights,2 yet only a
subset of cases can be attributed to inherited mutations;
single nucleotide polymorphisms (SNPs); or environ-
mental elements4,5 (Tables 1 and 2). In fact, only a small
portion of FPC cases are related to specific inherited syn-
dromes, such as hereditary breast-ovarian cancer (eg
BRCA2), Peutz-Jeghers syndrome, Lynch syndrome (or
hereditary nonpolyposis colorectal carcinoma), familial
adenomatous polyposis, ataxia-telangiectasia, hereditary
pancreatitis, and familial atypical multiple mole mela-
noma (Table 1).7 The remaining FPC cases have not
been attributed to a common driving inherited genetic
alteration. It was recently reported that the frequent ge-
netic drivers (ie Kras and TP53) of FPC are virtually iden-
tical to the drivers of sporadic PDA.3
Together, these and other studies support the notion
that unidentified genetic susceptibility alterations exist,
along with interactions with the environment or host
(eg the immune system) that cooperate to influence the
unusual frequency of PDA found in certain families (ie
FPC). Single nucleotide polymorphisms are subtle genetic
alterations that are frequently found in the general popu-
lation (>1%); inherited; and not classified as somatic-
tumor mutations. Associations have been made with
SNPs and FPC (Table 2); however, these associations
cannot completely explain FPC susceptibility found in
high-risk individuals, with the best odds ratios not reach-
ing the influence of smoking as a risk factor (eg odds ratio
< 2.0).8
We previously carried out expression and genotype
analysis of the indoleamine 2,3-dioxygenase-2 (IDO2)
gene in sporadic PDA.9 The IDO2 gene is adjacent to
and structurally similar to the IDO1 gene on chromo-
some 8p12.10 Functionally, IDO2 is also similar to its
paralog, IDO1, in that it can catabolize tryptophan.
Notably, several studies have shown that the IDO sys-
tem (both the IDO1 and IDO2 genes) functions in
restraining the activity of the immune system in its in-
teractions with multiple tumor systems.11 Previous
work has postulated that functional IDO2 enzymatic ac-
tivity represses immune responses in a host, which in
turn, facilitates PDA tumorigenesis. In theory, a func-
tional IDO2 enzyme in tumor cells could aid PDA to
avoid the immune system. Alternatively, Køllgaard and
colleagues12 demonstrated that a functionally intact
IDO2 enzyme could be presented to elicit an immune
response compared with an inactive IDO2 protein.
We previously discovered and described the presence
of 2 loss-of-function polymorphisms within the coding
region of the IDO2 gene, with a high prevalence in
the general population.10 The 2 SNPs are the R248W
polymorphism, defined as having a >90% reduction
in IDO2 catalytic activity and the Y359STOP polymor-
phism, generating a premature stop codon, completely
inactivating IDO2 activity10 (Fig. 1). Taking into ac-
count the importance of chronic inflammation on
PDA pathogenesis and based on previous work showing
IDO2’s role in immune regulation, we used our vast
PDA clinical database (the Jefferson Pancreatic Tumor
Registry) and patient population to determine whether
the IDO2 genotype had any correlation to FPC
susceptibility.
Table 1. Inherited Syndromes and Associated Lifetime Risk of Pancreatic Ductal Adenocarcinoma
Inherited syndrome Lifetime risk of pancreatic cancer
Hereditary breast and ovarian cancer syndrome, RR* 3.5e5.9
Peutz-Jeghers syndrome, % 11e36
Hereditary pancreatitis, % 25e40
Hereditary nonpolyposis colorectal cancer syndrome (Lynch syndrome), % 3.7
Familial atypical multiple mole melanoma, % 17
Familial adenomatous polyposis, % 1.7
*Relative risk (RR) associated with BRCA2 specifically. Data obtained from multiple sources.5,6
Abbreviations and Acronyms
FPC ¼ familial pancreatic cancer
HW ¼ Hardy-Weinberg
IDO2 ¼ indoleamine 2,3-dioxygenase-2
PCR ¼ polymerase chain reaction
PDA ¼ pancreatic ductal adenocarcinoma
SNP ¼ single nucleotide polymorphism
TJUH ¼ Thomas Jefferson University Hospital
Vol. 226, No. 4, April 2018 Nevler et al Genotyping in Familial Pancreatic Cancer 597
MATERIALS AND METHODS
Patient population
The cohort used for this data set included 79 patients
(approximately 130 normal and tumor tissue samples)
diagnosed with PDA, who underwent primary pancreatic
resection at the Thomas Jefferson University Hospital
(TJUH) between August 2006 and February 2013.
Patients in the study all had available tissue for DNA
analysis. Medical history, preoperative laboratory tests,
surgical and histologic findings, and oncologic follow-
up data were recorded from the patients’ medical records.
Cases in which the index patient had at least 1 first-degree
relative with a history of PDA were considered FPC, and
the rest of the cases were classified as sporadic PDA. We
used the Jefferson Pancreatic Tumor Registry as a valuable
resource to evaluate whether the indexed patient’s tumor
was classified as FPC. The Jefferson Pancreatic Tumor
Registry is IRB approved, and participating patients pro-
vided appropriate informed consent.
DNA sequencing of IDO2 polymorphisms
Genomic DNA from surgically resected pancreatic tissue
specimens (normal and tumor tissues, n ¼ 79 patients)
was isolated using the DNAeasy Blood and Tissue Kit
genomic DNA purification kit (Qiagen Inc). Polymerase
chain reactions (PCR) were used to amplify exons contain-
ing the IDO2 coding region polymorphisms rs4503083
and rs10109853, based on previously validated primer
sets (R248W (rs10109853) Forward Primer 50-GAA-
CATTCTATCCCCCGTTGC-30; R248W (rs10109853)
Reverse Primer 50-TTACCTGAGAGTGGATCCCTAG-
CA-30; Y359Stop (rs4503083) Forward Primer 50-TCTT-
GTGCTCCCTCCAAAACA-30; Y359Stop (rs4503083)
Reverse Primer 50-TGGTTTGGCTTCCCATGCTT-
30).10 The PCR reactions were performed in 25 mL reac-
tions using 2 mL DNA, 0.5 U/mL Taq polymerase
(USB), 2.5 mL 10 PCR buffer (USB), and 0.5 mL
10 mM dNTP Mix (Invitrogen). Conditions were set for
35 cycles at (95C for 2 minutes, 95C for 30 seconds,
55C for 30 seconds, 72C for 30 seconds, followed by
an extension of 4 minutes at 72C). Sequencing reactions
Figure 1. Representative chromatograms of direct sequencing of
patient constitutional genomic DNA showing the 3 possible se-
quences of homozygous, heterozygous, or wild-type sequence:
R248W polymorphism (left) and Y359STOP (right).
Table 2. Inherited Syndromes, Related Genes, and Single Nucleotide Polymorphisms Associated with Familial Pancreatic
Cancer
Familial disorder Genetic mutation
Hereditary breast and ovarian cancer syndrome BRCA1, BRCA2, PALB2, ATM
Peutz-Jeghers syndrome STK11/LKB1
Hereditary pancreatitis PRSS1, SPINK1
Hereditary nonpolyposis colorectal cancer syndrome (Lynch syndrome) Mismatch repair genes (HNPCC)
Familial atypical multiple mole melanoma p16 (CDKN2A or MTS1)
Familial adenomatous polyposis APC
1q32.1 (NR5A2 or LRH-1) rs3790844 (A>G), rs10919791 (G>A)
5p15.33 (CLPTM1/TERT) rs401681 (C>T)
6q25.3 (FOXQ1) rs9502893 (C>T)
9p34.2 (ABO) rs505922 (A>G)
12p11 (BICD1) rs708224 (A>G)
13q22.1 (KLF5) rs9543325 (C>T), rs9564966, (A>G)
APC, adenomatous polyposis coli; ATM, ataxia-telangiectasia; HNPCC, hereditary nonpolyposis colorectal carcinoma. Data obtained from multiple
sources.5,6
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included PCR purified products using DNA purification
columns (Qiagen) and the forward primers for each PCR
reaction. Each PCR reaction was separated by DNA elec-
trophoretic separation on a 0.75% DNA agarose gel.13
Sequencing was then performed by capillary electropho-
resis in the Sidney Kimmel Cancer Center DNA core fa-
cility at Thomas Jefferson University. Genotyping steps
were blinded and annotated by number to clinical data
and familial-sporadic patient status. The representative
sequencing chromatograms were used to identify a
wild-type, heterozygous, or homozygous IDO2 genotype
(see Fig. 1). Genotypes considered as resulting in inacti-
vation of the IDO2 enzyme (Y325Stop homozygous and
R248W homozygous) were categorized as the homozy-
gous group, and the other genotypes were grouped as
wild-type or loss-of-function heterozygous. All geno-
types provided in this study reflect the germline and
were not from microdissected samples enriched with
neoplastic cells.
Genetic distribution data from the 1000 Genomes
Project. The 1000 Genomes Project is a global effort to
map, through sequencing, human genetic variation across
the globe (ie a global reference for human genetic varia-
tion).14 In brief, it contains genetic variation data of
more than 2,500 subjects from around the world. The
data were obtained through a planned sequencing of
target populations and, as such, can be divided into spe-
cific geographical subsets. The CEU subset (Utah resi-
dents with northern and western European ancestry)
was selected to serve as a genetic distribution control
due to its closeness to the TJUH patient cohort in terms
of ethnoracial distribution.
Statistical analysis
Genotype distributions of each polymorphism were
analyzed for Hardy-Weinberg (HW) deviation using
chi-square test and Fisher’s exact test. A genotype distri-
bution set of Utah residents with northern and western
ancestry available from the 1000 genomes project
(CEU, n ¼ 99) was used as a genetic control for
distribution comparisons. Distribution comparisons
were also performed using chi-square test and Fisher’s
exact test. Age, sex, tobacco use, familial history positive
for any type of cancer, R248W genotype, Y359Stop geno-
type, and IDO2 homozygous status were assessed individ-
ually for association with FPC. Correlative analysis was
performed using Spearman’s test. Factors with p < 0.2
were subsequently included in a multivariate regression
model for correlation with FPC. The model was further
optimized by sequential exclusion of statistically non-
relevant factors (p  0.2) until achievement of a final
optimal model fit (p  0.05). A p value  0.05 was
considered statistically significant. Statistical analysis was
performed using IBM SPSS, version 20 (IBM Corp).
RESULTS
An increased frequency of the Y359Stop SNP but not the
R248W SNP uncovered in FPC patients. Sanger
sequencing revealed that 52 cases (66%) of the TJUH
cohort had the wild-type Y359/Y359 genotype configura-
tion, 19 (24%) had the Y359/Y359Stop configuration
and 8 (10%) had the homozygous IDO2 inactive
Y359Stop/Y359Stop configuration (see Fig. 1 for chro-
matograms for Sanger sequencing and Table 3 for distri-
butions). From this analysis, a statistically significant
deviation from the HW equilibrium was noted in the
TJUH cohort (p < 0.05) with under-representation of
the Y359/Y359Stop heterozygous genotype. Stratification
of FPC and sporadic PDA did not reveal a significant
HW disequilibrium with the chi-square test. However,
Fisher’s exact test (employed due to the small size of the
subsets) suggested a trend toward HW disequilibrium
(p ¼ 0.08). Allelic distributions between the FPC and
CEU control cohorts were 50% vs 55% with a Y359/
Y359 configuration, 22% vs 38% with a Y3598/
Y359Stop configuration and 28% vs 7% with the
completely inactive Y359Stop/Y359Stop configuration
(Table 3). The frequency of Y359STOP alleles signifi-
cantly correlated with increased rates of FPC compared
Table 3. Overall Association of Indoleamine-2,3-Dioxygenase-2 Genotypes to Thomas Jefferson University vs Control
Cohorts
IDO2 genotype
R248 (WT)
R248W
(hetero-)
R248W
(homo-) Y359 (WT)
Y359Stop
(hetero-)
Y359Stop
(homo-)
n % n % n % n % n % n %
TJUH cohort, n ¼ 79 25 32 39 49 15 19 52 66 19 24 8 10
TJUH FPC cohort, n ¼ 15 6 40 4 27 5 33 7 46 4 27 4 27
CEU control cohort, n ¼ 99 26 27 44 44 29 29 54 55 38 38 7 7
CEU, Utah residents with northern and western European ancestry; FPC, familial pancreatic cancer; Hetero-, heterozygous; Homo-, homozygous; IDO2,
indoleamine-2,3-dioxygenase-2; TJUH, Thomas Jefferson University Hospital; WT, wild-type.
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with sporadic PDAs (Fig. 2A, p < 0.05), resulting in
increased rates of FPC in Y359STOP heterozygous carriers
and even higher rates in Y359STOP homozygous patients
(50%). Furthermore, overall comparison of Y359Stop
genotype distribution demonstrated a strong trend show-
ing a greater representation of the Y359Stop/Y359Stop
Spearman’s ρ=0.23 
P<0.05 
N=52 N=19 N=8 
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Figure 2. Functionally inactive indoleamine-2,3-dioxygenase-2 (IDO2) alleles are frequently found in familial
pancreatic cancer (FPC) patients. (A) Prevalence of FPC in various Y359Stop genotypes (wild-type, heterozygous, and
homozygous) in the entire Thomas Jefferson University Hospital (TJUH) cohort (FPCs and sporadic pancreatic ductal
adenocarcinoma [PDA]). Spearman’s correlation test (r ¼ 0.229, p < 0.05). (B) Y359Stop genotype distribution in
FPC as compared with CEU (Utah residents with northern and western European ancestry) control cases. chi-square
test, 2  3 comparison, p ¼ 0.054. WT, wild type. (C) Rates of FPC in various R248W genotypes. Spearman’s
correlation test (r ¼ 0.028, p ¼ NS) in the entire TJUH cohort (FPCs and sporadic PDA). (D) R248W genotype
distribution in FPC compared with CEU control cases. Chi-square test, 2  3 comparison, p ¼ NS.
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configuration in the FPC subset compared with the CEU
normal control group (Fig. 2B, p ¼ 0.054).
By way of comparison, Sanger sequencing determined
that 25 cases (32%) of the TJUH cohort had a R248/
R248 genotype configuration, 39 (49%) had a R248/
R248W configuration, and 15 (19%) had the homozygous
R248W/R248W configuration. Overall and with stratifi-
cation to FPC and sporadic PDA, this genotype distribu-
tion did not deviate from the HW equilibrium. Allelic
distributions among the FPC and CEU control cohorts
33% vs 27% with an R248/R248 genotype configuration,
28% vs 44% with an R248/R248W configuration and
39% vs 29% with a homozygous R248W/R248W config-
uration (Fig, 2C, Table 3). Fisher’s exact test revealed no
significant differences in genotype distribution between
the TJUH cohort (or its sub-populations) and the CEU
control group. The R248W polymorphism, although hav-
ing slightly increased FPC rates with the homozygous
configuration (39%) compared with the heterozygous
and wild-type genotypes (33% and 28%, respectively),
did not significantly correlate with FPC (Fig. 2D).
The combined homozygous group (Y359STOP and
R248W) was strongly associated with FPC (Fig. 3),
with an odds ratio of 5.4 (95% CI 1.6 to 17.6; p <
0.01) compared with sporadic PDA cases. Taken
together, these data demonstrated that in our cohort the
inactive IDO2 genotype (ie the homozygous group) corre-
lated with individuals with FPC compared with the con-
trol cohort or patients with sporadic PDA (Fig. 3).9 A full
bivariant distribution table is available (Table 4).
Evaluations of clinical risk factors for FPC were not sig-
nificant in these cohorts. Age, sex, smoking, and familial
cancer history were not associated with FPC. However,
due to a large body of work linking smoking to PDA
and increased risk for PDA in families with known
PDA,15,16 we included smoking in 3 separate regression
models (with Y359Stop, R248W, and the combined ho-
mozygous grouping). A regression model analyzing the
interaction of the combined IDO2 homozygous status
with smoking status showed the non-homozygous geno-
types combined with non-active smoker status suggested
an association with a decreased risk for FPC
(nonsmoker/quit 15 years ago: relative risk 0.27; 95%
CI 0.6 to 1.1; p ¼ 0.07; quit <15 years ago: relative
risk 0.17; 95% CI 0.2 to 1.5; p ¼ 0.11).
DISCUSSION
Pancreatic ductal adenocarcinoma has an overall 5-year
survival rate of 9%.17 To date, the molecular drivers (eg
BRCA2 and PALB2) of PDA prevalence are only known
for a small percentage of high-risk families2 (Tables 1
and 2). In this study, we evaluated the frequency of
loss-of-function SNPs in the IDO2 gene in our institu-
tional patient population that contained FPC. Although
this was a small patient cohort, we found a high frequency
of the inactive, homozygous IDO2 genotype in FPC pa-
tients (see Figs. 2 and 3).
These data are compelling, yet this study has a number
of limitations. First, due to our limited numbers, we
restricted our definition of FPC to cases in which the in-
dex patient had at least 1 first-degree relative with a his-
tory of PDA. It is possible that our results would be
stronger if we included only patients with 2 or more
affected family members. Second, increasing our numbers
could dilute our positive signal in the FPC cohort. Third,
additional molecular correlates from the patients would
support our conclusions, including the knowledge of
any predisposing genotypes (eg BRCA2 mutations) or im-
mune signatures. Fourth, having more clinical data about
the individuals genotyped in this study including their
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Figure 3. Indoleamine-2,3-dioxygenase-2 (IDO2) genotype varia-
tions in familial pancreatic cancer (FPC) compared with sporadic
pancreatic ductal adenocarcinoma (PDA) cases and CEU (Utah
residents with northern and western European ancestry) control
cases. Chi-square/Fisher’s exact comparisons. OR, odds ratio.
Table 4. Bivariant Genotype Distribution of the Thomas
Jefferson University Cohort (n ¼ 79)
Genotype
Y359/
Y359
Y359/
Y359Stop
Y359Stop/
Y359Stop
R248/R248 15 6 4
R248/R248W 26 9 4
R248W/R248W 11 4 0
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history of autoimmune disorders or pancreatitis could be
informative. Finally, it would be interesting to see if in
IDO2 (þ/) heterozygote germline genotyped patients
there was evidence of selection for a loss of the wild-
type and/or SNP allele in the tumors of these patients.
In theory, these data appear counterintuitive, as an
inactive IDO2 host genotype has been predicted to pro-
duce an overactive immune system that would suppress
PDA tumorigenesis.9,10 According to this theory, an inac-
tive host IDO2 system (as indicated by homozygous loss
of function SNPs), can enable a heightened, pro-
inflammatory host environment that cooperates with
Kras activation to induce PDA tumorigenesis.18 Simply
put, an inactive host IDO2 genotype could contribute
to a tumor-promoting, inflammatory environment.19
Yet, the data from this study might support an opposing
theory of how the host immune (IDO) system can facili-
tate FPC tumorigenesis. Findings from Køllgaard and col-
leagues’12 work led them to postulate that individuals
harboring the inactive homozygous Y359STOP host ge-
notype are unable to mount a specific, IDO2-directed im-
mune response. The investigators discovered that specific
T cells primed against different HLA-A2-restricted pep-
tides derived from the IDO2 protein were restricted to
wild-type or heterozygous IDO2 genotyped individuals,
and no T-cell responses were observed in individuals ho-
mozygous for the Y359STOP IDO2 alleles. Therefore,
these data support the notion that to achieve an IDO2
specific T-cell response, an individual must have a func-
tional IDO2 enzyme (ie genotyped IDO2 heterozygous
or wild-type). A possible explanation for why the
R238W does not elicit a comparable effect is that,
although the R238W appears to interfere with substrate
accessibility to the active site, the Y359Stop allele elimi-
nates an essential histidine that, from studies of the
IDO1 enzyme, has been shown to be essential for coordi-
nating with the heme iron. Breaking this heme iron-
histidine bond results in conformational changes that
are thought to be responsible for enhanced proteosomal
degradation of IDO1. The Y359Stop allele might not
only abrogate activity, but could also lead to the elimina-
tion of the IDO2 protein itself, so that any non-enzymatic
effects it might have are also eliminated.
In the scenario mentioned, high-risk individuals who
are homozygous for the inactive IDO2 Y359Stop geno-
type might be unable to mount a proper immune
response against PDA cells due to the lack of presentable
IDO2 antigens. The evidence for these 2 opposing hy-
potheses highlights the dual-edged sword of the IDO2
system. That is, either dysregulated inflammation and/
or an inactive immune response can facilitate the tumor-
igenesis process. Ongoing studies in both a mouse model
for PDA tumorigenesis20,21 and human specimens are be-
ing performed to further investigate these countervailing
hypotheses.
CONCLUSIONS
Other possible implications of this study relate to early
detection and predictive biomarker strategies in the
PDA field. Future studies will demonstrate whether
high-risk individuals in FPC families, with unknown ge-
netic drivers, should be IDO2 genotyped. In one scenario,
these individuals could be identified for immune-
suppressing therapies in an effort to modify an overactive
host immune system facilitating PDA tumorigenesis.
More realistic deliverables of this work are the immediate
clinical implications for FPC patients with an inactive
IDO2 genotype. These patients might be refractory to
novel IDO inhibitor-based therapies, yet they might
respond better to other immune checkpoint therapies
(eg PD-1/PDL1 inhibitors).22 Larger-scale validation
studies and future retrospective studies from
immunotherapy-based clinical trials will be required to
assess the prognostic and predictive value of IDO2
genotyping.
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Discussion
DR SELWYN VICKERS (Birmingham, AL): I commend Drs Yeo
and Brody and your team for creating an outstanding clinical enter-
prise, and also for continuing to push the boundaries of science and
trying to address this difficult disease of pancreatic cancer. As you
look at the indoleamine-2,3-dioxygenase-2 (IDO2) molecule, but
particularly the Y-359 allele, it is fairly prevalent throughout human
species, but it has a unique distribution that is not uniform across
the racesdapproximately 12% in African Americans, and as high as
37% in Asians. Have you taken what the distribution is into
account in your familial allele, at least in your familial pancreatic
group? How does that compare with your validation cohort, which
is from the state of Utah? As you know, this is a very homogeneous
population. What impact does that have on the conclusion?
As it relates to a driver, with the prevalence of the allele, is it
likely that it is a driver? And if it is, how might you actually prove
it even more so in vivo? It may affect not only T cells, but the den-
dritic cells. And might this also be a selector? In some ways, if you
highlight it for precision medicine, might it be a selector for vaccine
therapy? Might these patients actually be more qualified for a vac-
cine trial because the immune system may have a prevalent role in
affecting dendritic cells?
As it relates to the broader picture, please give your thoughts on
the ability to further stratify patients in the context of either familial
disease or, as it relates to our sporadic disease, from using either
whole genome or exome sequencing looking for targeting muta-
tions. I think you really are onto something, that the immune sys-
tem is truly suppressed in major ways with pancreas cancer. Might
broader sequencing give you some ideas for targeted or at least
actionable targets related to immune checkpoint inhibitors?
DR CHRISTOPHER WOLFGANG (Baltimore, MD): I would like
to congratulate Drs Yeo and Brody on a well-done and important
study. It is yet another example of high-quality translational sci-
ence from this surgical group. The details of the study are quite
elegant, with sophisticated genetic work and a complex statistical
analysis. The authors demonstrated that inactivation of the IDO2
gene is linked to familial pancreatic cancer, and these results sug-
gest that this single nucleotide polymorphism (SNP) may play a
mechanistic role through alteration of immune function. The
conclusions have the potential to guide patient management in
the near future.
I would like to break from the obviously interesting findings of
this study to point out the importance of this work in terms of the
big picture, something that may be lost in the details of the presen-
tation unless one thinks often about cancer genetics. In past decade,
we, as a scientific community, have focused on cancer genomes and
the somatic mutations that occur within tumors. For pancreas can-
cer, this era was kicked off by Dr Bert Vogelstein and the Hopkins
group with the publication of the pancreatic cancer genome in the
journal Science in 2008. This somatic tumor sequence is important
because it serves as the code book for tumor behavior. However, tu-
mor behavior is not realized at the level of the genotypedit is real-
ized at the level of the phenotype. Tumors are a population of cells
that initiate and grow under many of the same principles as do an
animal species.
In Darwinian evolution, it is the phenotype, not the genotype,
which is selected by the environment. The environment in which a
species evolves influences the characteristics of the animaldpolar
bears are big, hairy, and white, all adaptations to their environment.
When we study cancer genomes to study the development of cancer,
we ignore the environment inwhich tumor grows. You can only learn
somuch about the polar bear by studying it in the zoo.Dr Yeo and his
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